Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 14:15:173-183.
doi: 10.2147/SAR.S475807. eCollection 2024.

Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes

Caleb J Banta-Green  1   2   3 , Mandy D Owens  1   4 , Jason R Williams  1 , Anthony S Floyd  1 , Wendy Williams-Gilbert  1 , Susan Kingston  1
Affiliations

Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes

Caleb J Banta-Green et al. Subst Abuse Rehabil. .

Abstract

Purpose: A large treatment gap exists for people who could benefit from medications for opioid use disorder (MOUD). People OUD accessing services in harm reduction and community-based organizations often have difficulty engaging in MOUD at opioid treatment programs and traditional health care settings. We conducted a study to test the impacts of a community-based medications first model of care in six Washington (WA) State communities that provided drop-in MOUD access.

Participants and methods: Participants included people newly prescribed MOUD. Settings included harm reduction and homeless services programs. A prospective cohort analysis tested the impacts of the intervention on MOUD and care utilization. Intervention impacts on mortality were tested via a synthetic comparison group analysis matching on demographics, MOUD history, and geography using WA State agency administrative data.

Results: 825 people were enrolled in the study of whom 813 were matched to state records for care utilization and outcomes. Cohort analyses indicated significant increases for days' supply of buprenorphine, months with any MOUD, and months with any buprenorphine for people previously on buprenorphine (all results p<0.05). Months with an emergency department overdose did not change. Months with an inpatient hospital stay increased (p<0.05). The annual death rate in the first year for the intervention group was 0.45% (3 out of 664) versus 2.2% (222 out of 9893) in the comparison group in the 12 months; a relative risk of 0.323 (95% CI 0.11-0.94).

Conclusion: Findings indicated a significant increase in MOUD for the intervention group and a lower mortality rate relative to the comparison group. The COVID-19 epidemic and rapid increase in non-pharmaceutical-fentanyl may have lessened the intervention impact as measured in the cohort analysis. Study findings support expanding access to a third model of low barrier MOUD care alongside opioid treatment programs and traditional health care settings.

Keywords: harm reduction; low-barrier care; medications for opioid use disorder; multi-site study; opioid use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests in this work.

Similar articles

See all similar articles

Cited by

References

    1. Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019”. Int J Drug Policy. 2022;110:103786. doi:10.1016/j.drugpo.2022.103786 - DOI - PMC - PubMed
    1. Hser YI, Zhu Y, Fei Z, et al. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022;117(1):151–161. doi:10.1111/add.15594 - DOI - PMC - PubMed
    1. Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298–308. doi:10.1111/add.13193 - DOI - PMC - PubMed
    1. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Internal Med. 2018;169(3):137. 10.7326/M17-3107 - DOI - PMC - PubMed
    1. McMahan VM, Kingston S, Newman A, Stekler JD, Glick SN, Banta-Green CJ. Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. Drug Alcohol Depend. 2020;216. doi:10.1016/j.drugalcdep.2020.108243 - DOI - PMC - PubMed

LinkOut - more resources